arrow
S

Susana Banerjee

royal marsden nhs foundation trust
H指数:71
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term efficacy and safety of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201

奥拉帕尼联合达芬钦在复发性低级别浆液性卵巢癌中的长期疗效与安全性:ENGOT-OV60/GOG-3052/RAMP 201研究2年随访结果

2026-09-010
OAAI
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses

曲妥珠单抗德鲁替康在DESTINY-PanTumor02研究中对HER2表达妇科癌症的抗肿瘤活性、安全性和探索性生物标志物分析

2026-05-010
PRE
Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer

叶酸受体α表达型复发性铂敏感卵巢癌中mirvetuximab soravtansine联合卡铂的治疗效果

2026-04-230
PRE
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

Ib期临床试验:评估SL-172154(一种双特异性CD47抑制剂和CD40激动剂Fc融合蛋白)联合mirvetuximab soravtansine或脂质体多柔比星治疗铂耐药性卵巢癌患者的疗效。

2026-04-080
PRE
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201

阿伐木单抗与德法他尼联用治疗复发性低级别浆液性卵巢癌:ENGOT-OV60/GOG-3052/RAMP 201 II期临床试验的通俗语言总结

2025-12-120
OAAI
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer

髓系细胞网络调控复发性卵巢癌中原有免疫景观的重新建立

2025-07-310
OAAI
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

德法替尼联合阿瓦替尼治疗实体瘤患者: 1期框架试验

2025-06-270
OAAI
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial

Rucaparib用于铂敏感、复发性卵巢癌的维持治疗:III期、随机、安慰剂对照ARIEL3试验的最终结果

2025-06-170
OA
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprogramming of the tumour microenvironment (vol 15, 1500570, 2024)

通过细胞外囊泡介导的微小RNA重编程肿瘤微环境以增强溶瘤病毒疗法 (vol 15, 1500570, 2024)

2025-04-220
OA
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301:一项评估阿伏莫替尼联合达法他尼与研究者选择治疗方案相比,在复发性低级别浆液性卵巢癌患者中的随机III期试验

2025-04-190
OAAI
Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

肿瘤学专业人士对危机时期改善工作场所福祉和健康的看法与建议:来自ESMO韧性工作组调查系列的质性主题分析

2025-03-010
OAAI
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

研究总结: 通过招募HER2 IHC状态: DESTINY-PanTumor02的事后分析,曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

2025-03-010
OAAI
Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment

通过细胞外囊泡介导的microRNA重新编程肿瘤微环境来增强溶瘤病毒治疗

2024-12-230
OAAI
Two decades of advances in clinical oncology - lessons learned and future directions

临床肿瘤学二十年的进展-经验教训和未来方向

2024-10-011
PRE
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

通过纳入HER2 IHC状态: DESTINY-PanTumor02的事后分析,曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

2024-09-111
OAAI